You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SGLT2 inhibitors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Kidney Injury Trial (SGLT2 inhibitor)

Not yet recruiting
  • Acute Kidney Injury
  • SGLT2 inhibitor
  • (no location specified)
Nov 3, 2023

Transplant; Failure, Heart, Cardiac Allograft Vasculopathy, Rejection Heart Transplant Trial (SGLT2i)

Not yet recruiting
  • Transplant; Failure, Heart
  • +2 more
  • (no location specified)
Nov 19, 2023

Polycystic Ovary Syndrome Trial (SGLT2 inhibitors combined with metformin, Placebo combined with metformin)

Not yet recruiting
  • Polycystic Ovary Syndrome
  • SGLT2 inhibitors combined with metformin
  • Placebo combined with metformin
  • (no location specified)
Jul 21, 2023

Heart Failure Acute, Ventilator Lung Trial in Taipei (SGLT2 inhibitor)

Recruiting
  • Heart Failure Acute
  • Ventilator Lung
  • SGLT2 inhibitor
  • Taipei, Taiwan
    National Taiwan University Hospital
Nov 16, 2023

SLE, Lupus Nephritis, SGLT2 Inhibitors Trial in Mansoura (dapagliflozin, )

Active, not recruiting
  • SLE
  • +2 more
  • Mansoura, Egypt
    Urology and Nephrology Center
Feb 18, 2023

The Triglyceride/Glucose Index and SGLT-2 Inhibitors

Recruiting
  • Metabolic Disease
  • Diabetes
  • SGLT-2 inhibitors
  • Samsun, İlkadım, Turkey
    Samsun Education and Research Hospital
Jun 14, 2023

Type 2 Diabetes, Type 1 Diabetes Trial in San Antonio (Empagliflozin 25 MG, Placebo)

Not yet recruiting
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Empagliflozin 25 MG
  • Placebo
  • San Antonio, Texas
    Texas Diabetes Institute/UH
Jul 31, 2023

Obesity, Weight Loss Trial in Birmingham (Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination)

Not yet recruiting
  • Obesity
  • Weight Loss
  • Empagliflozin Arm
  • +3 more
  • Birmingham, Alabama
    University of Alabama at Birmingham
May 22, 2023

Heart Failure, Hypertension, Left Ventricle Remodeling Trial (Empagliflozin 10 MG, Placebo)

Not yet recruiting
  • Heart Failure
  • +3 more
  • Empagliflozin 10 MG
  • Placebo
  • (no location specified)
Sep 20, 2023

Cancers Among Diabetics ,Observational Study

Enrolling by invitation
  • Cancer
  • +3 more
  • interleukin 6
  • Riyadh, N/A (Non-US), Saudi Arabia
    ministry of health , First health cluster , Riaydh
Oct 28, 2022

SGLT2 INHIBITORS, Lupus Nephritis, BMD Trial in Mansoura (Dapagliflozin tablet, )

Active, not recruiting
  • SGLT2 INHIBITORS
  • +2 more
  • Dapagliflozin tablet
  • placebo
  • Mansoura, Egypt
    Urology and Nephrology Center
Jan 19, 2023

Type 2 Diabetes Trial (SGLT2 inhibitor)

Not yet recruiting
  • Type 2 Diabetes Mellitus
  • SGLT2 inhibitor
  • (no location specified)
Feb 12, 2023

Prediabetic State, Impaired Fasting Glucose, Impaired Glucose Tolerance Trial in Beijing (Dapagliflozin 10mg Tab, lifestyle

Not yet recruiting
  • Prediabetic State
  • +2 more
  • Dapagliflozin 10mg Tab
  • lifestyle interventions
  • Beijing, Beijing, China
    Peking University Third Hospital
Jun 19, 2023

SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac

Recruiting
  • Coronary Artery Disease
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Shah Alam, Selangor, Malaysia
    Institute for Clinical Research, National Institutes of Health,
Nov 9, 2023

SGLT2 for Heart Failure in CHD Patients

Not yet recruiting
  • Heart Failure
    • Nice, France
      University hospital of Nice
    Jun 7, 2023

    SGLT2 Inhibition in Heart Failure

    Recruiting
    • Heart Failure
    • Sodium-glucose cotransporter 2 inhibitor
    • Belfast, United Kingdom
      Belfast Health and Social Care Trust
    Nov 15, 2023

    SGLT2-I Use in DFUD: a Delphi Study

    Not yet recruiting
    • Diabetic Foot Ulcer
    • eDelphi method
    • (no location specified)
    Aug 14, 2023

    Heart Failure Trial in Denmark (Digital letter)

    Recruiting
    • Heart Failure
    • Digital letter
    • Copenhagen, Denmark
    • +4 more
    Jun 5, 2023

    SGLT2 Inhibitors and Hemoglobin

    Recruiting
    • Diabetes Mellitus, Type 2
    • SGLT2 inhibitor
    • Patras, Greece
      University Hospital of Patras
    Jun 2, 2022

    Type2 Diabetes, Heart Failure With Preserved Ejection Fraction Trial in San Antonio (Empagliflozin 25 MG, Placebo)

    Recruiting
    • Type2 Diabetes
    • Heart Failure With Preserved Ejection Fraction
    • Empagliflozin 25 MG
    • Placebo
    • San Antonio, Texas
    • +1 more
    Jan 21, 2023

    SGLT-2 Inhibitors in the Treatment of Ascites

    Recruiting
    • Ascites Hepatic
    • +2 more
    • SGLT2 inhibitor
    • Palermo, Italy
    • +1 more
    Aug 11, 2023

    Cystinuria Trial in San Francisco (Dapagliflozin)

    Recruiting
    • Cystinuria
    • San Francisco, California
      University of California, San Francisco
    Oct 4, 2022

    Left Ventricular Remodeling in Type 2 Diabetic Acute Myocardial

    Recruiting
    • Myocardial Infarction
    • Diabetes Mellitus, Type 2
    • SGLT2 inhibitor
    • Seoul, Korea, Republic of
      Seoul St. Mary's Hospital
    Mar 5, 2023

    Called FLAMINgO to Learn More About Treatment Combination of

    Active, not recruiting
    • Chronic Kidney Disease
    • Type 2 Diabetes
    • Finerenone (Kerendia, BAY94-8862)
    • Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
    • Whippany, New Jersey
      Bayer
    Jan 19, 2023

    Therapeutic Drug Use for CKD Patients

    Active, not recruiting
    • Chronic Kidney Disease
    • angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
    • Jinan, Shandong, China
      Xiao Li，MD
    Apr 18, 2023